Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Research and Development Expenses and Reimbursements Due

Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2016 and 2015, is presented as follows:



	Three months ended March 31,
	2016		2015
Research and development expense, gross	$	4,962	$	3,981
Less: Reimbursement of research and development expense	219		194
Research and development expense, net of reimbursements	$	4,743	$	3,787

Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.



	Three Months Ended March 31,
	2016	2015
Warrants to purchase Series C-1 Preferred	14,033	14,033
Stock options	1,450,453	575,416